Synairgen plc (LON:SNG – Get Free Report) shares dropped 12.1% on Thursday . The company traded as low as GBX 4.31 ($0.06) and last traded at GBX 4.31 ($0.06). Approximately 94,904 shares were traded during mid-day trading, a decline of 73% from the average daily volume of 349,617 shares. The stock had previously closed at GBX 4.91 ($0.06).
Synairgen Trading Up 6.3 %
The stock has a market cap of £9.65 million, a P/E ratio of -159.67 and a beta of -2.23. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.77 and a quick ratio of 6.35. The stock’s 50-day moving average is GBX 3.86 and its two-hundred day moving average is GBX 5.03.
About Synairgen
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease.
See Also
- Five stocks we like better than Synairgen
- How to Evaluate a Stock Before Buying
- Survey Reveals: America’s Most Coveted Businesses in 2024
- What is the S&P/TSX Index?
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Health Care Stocks Explained: Why You Might Want to Invest
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.